… Heart Failure Registry show that a great number of patients … population, 80% of patients
were eligible for dapagliflozin … and dapagliflozin in HFmrEF and HFpEF, we observed similar …

… the eligibility in a real-world heart failure population for the DAPA-HF (testing dapagliflozin)
and … the eligible real-world patients to trial participants and to characterize the noneligible …

… eligible for dapagliflozin according to the key criteria of the DAPA-HF trial. The main reason
for non-eligibility … patients were eligible for dapagliflozin according to the DAPA-HF trial key …

… In our cohort, the high prevalence of patients with LVEF >40% or impaired kidney function
suggests that existing comorbidities have a significant weight both on prognosis and on …

… proportion of patients meeting FDA label criteria for dapagliflozin of all eligible patients with
HFrEF at … As DAPA-HF evaluated a population of patients with chronic HFrEF, we focused on …

… in worsening heart failure (HF) and cardiovascular death. It is … of patients admitted to a large
regional cardiac centre with decompensated heart failure would be eligible for dapagliflozin …

… % of all heart failure admissions and 55% of patients with HFrEF would be eligible for
dapagliflozin post-discharge … There were no patients with T1DM in our study population. Of the …

… Eligible participants were randomized 1:1 to dapagliflozin 10 mg once daily or matching …
and clinicians regarding the initiation and long-term use of dapagliflozin in this population. …

… who have been hospitalized for HF represent an important target population for reducing …
and are most directly relevant to patients who meet the trial enrollment criteria. Second, the …

… were selected according to specific inclusion and exclusion criteria, and our findings may
not apply to all patients with HFmrEF or HFpEF in the broader population. Hospitalization rates …